Association between methylenetetrahydrofolate reductase C677T polymorphism and epilepsy susceptibility: A meta-analysis

PurposeMethylenetetrahydrofolate reductase (MTHFR) C677T polymorphism has been implicated as a potential risk factor for epilepsy. To date, many case–control studies have investigated the association between MTHFR C677T polymorphism and epilepsy susceptibility. However, those findings were inconsistent. The objective of this study is to evaluate the precise association between MTHFR C677T polymorphism and epilepsy.MethodsAn electronic search of PubMed, EMBASE for papers on the MTHFR C677T polymorphism and epilepsy susceptibility was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the association.ResultsTen case–control studies containing 1713 cases and 1867 controls regarding MTHFR C677T polymorphism were selected. A significant association between the MTHFR C677T polymorphism and epilepsy susceptibility was revealed in this meta-analysis (for T vs. C: OR = 1.19, 95% CI = 1.08–1.32; for TT + CT vs. CC: OR = 1.20, 95% CI = 1.05–1.38; for TT vs. CC: OR = 1.48, 95% CI = 1.20–1.83; for TT vs. CT + CC: OR = 1.35, 95% CI = 1.12–1.64). In subgroup analysis by ethnicity, the results also indicated the association between the MTHFR C677T polymorphism and epilepsy susceptibility within the Asian populations (for T vs. C: OR = 1.55, 95% CI = 1.15-2.07; for TT + CT vs. CC: OR = 1.67, 95% CI = 1.08-2.59; for TT vs. CC: OR = 2.33, 95% CI = 1.30-4.20; for TT vs. CT + CC: OR = 1.89, 95% CI = 1.12-3.18).ConclusionThe results indicated that MTHFR C677T polymorphism was associated with an increased risk of epilepsy. However, further studies in various regions are needed to confirm the findings from this meta-analysis.